ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
ArriVent BioPharma (AVBP) PT Raised to $36 at Citi
September 10, 2024 11:49 AM EDTCiti analyst Yigal Nochomovitz raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $36.00 (from $30.00) while maintaining a Buy rating.
The analyst comments "Today, AVBP shared data from the Ph1b FURTHER study evaluating firmonertinib in 1L+ EGFR PACC mutations at WCLC. The... More
